Evidence check: COMT in the context of weight loss

The evidence for COMT in the context of weight loss is weak and largely mechanistic. COMT (catechol-O-methyltransferase) degrades catecholamines like dopamine and norepinephrine, which influence mood, appetite, and energy balance. The well-studied Val158Met variant (rs4680) reduces enzyme activity, potentially increasing dopamine availability. In theory, this could affect reward-driven eating or metabolic rate, but effect sizes are small and inconsistent. The provided context only supports a mechanistic link to stress resilience, not weight loss. No direct human studies in the context demonstrate a meaningful impact of COMT variants on weight loss outcomes. Consumer genetic tests often overclaim such associations. Lifestyle factors—caloric deficit, physical activity, sleep—dominate weight regulation. Currently, no evidence-based dietary or supplement strategy exists for COMT-based weight loss personalization. Safety note: Do not alter diet or supplements based solely on this gene. Conclusion: Mechanistically plausible but clinically unsupported for weight loss.